In 1995, a phase I/II study assessed the efficacy of a high-dose cyclophosphamide regimen combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) for treating malignant brain tumors. This evidence concerns the gene CSF2 and brain cancer.